Drug recall · March 29, 2017
Quillivant XR recall
Why: Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017 Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).
- Lots / codes
Lot #: 03216026A, Exp. 02/18
- Quantity
- 11,862 units
- Company
- Pfizer Inc, Peapack, NJ
- Distribution
- Nationwide within US
- Initiated
- March 7, 2017 · Voluntary: Firm initiated
- Classified
- March 22, 2017
- Reported
- March 29, 2017
- Ended
- May 31, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Methylphenidate
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.